GLP1R and cardiovascular disorder: In addition, the study showed that the risk of MACE in T2DM patients with a history of cardiovascular disease was significantly reduced by 14%, while the risk of MACE in patients without a history of cardiovascular disease was significantly reduced by 6%.345,347 In addition, the use of GLP-1 RAs in nondiabetic patients has focused on a modest improvement in left ventricular function after 7 days of acute treatment with the GLP-1 RA in patients with ST-segment elevation myocardial infarction (STEMI).348,349 Similar results were seen in patients without STEMI, independent of diabetes status.